Patents Examined by Kimberly R. Jordan
  • Patent number: 5776430
    Abstract: The combination of chlorhexidine gluconate (CHG), SDA-3 ethyl alcohol and cetyl lactate has produced a highly effective topical antimicrobial cleanser having immediate, persistant and residual bactericidal activity. The invention also relates to a low temperature manufacturing process for producing chlorhexidine salts in alcohol based formulations.
    Type: Grant
    Filed: August 20, 1996
    Date of Patent: July 7, 1998
    Assignee: Calgon Vestal, Inc.
    Inventors: David W. Osborne, Fred Kirchner
  • Patent number: 5573765
    Abstract: A composition for the treatment of vaginal yeast which promotes normal vaginal bacterial growth during treatment, comprising a yeast-inhibitory agent selected from one or more of the group consisting of ethylene glycol, propylene glycol, and glycerol, an effectively buffered aqueous acetate solution and cells of a Lactobacillus species. In the composition the concentration of acetate is effective to establish a pH of the composition in the range of from about 5 to about 7, the presence of unionized acetate inhibits yeast selectively compared to the bacteria, and the proportions of the yeast inhibitory agent and the buffering solution are effective to allow the active yeast-inhibitor agent to inhibit the vaginal yeast Candida. A method of treatment of vaginal yeast while promoting normal vaginal bacterial growth, by intravaginal application of the composition described above, is disclosed.
    Type: Grant
    Filed: August 13, 1994
    Date of Patent: November 12, 1996
    Assignee: Mark S. Reinhard
    Inventors: Mark S. Reinhard, Byron T. Burlingham
  • Patent number: 5510341
    Abstract: An ovulation-inhibiting preparation for hormonal contraception, comprising two hormone constituents packed spatially separate in a packing unit intended for chronological, sequential oral administration, said constituents each comprising a plurality of daily hormone units accommodated spatially separate and individually removable in the packaging unit. The first hormone constituent consists essentially of an estrogen preparation which effects a disturbance of the follicle stimulation; the second hormone constituent consists of an estrogen preparation and a gestagen preparation in a dose at least adequate for inhibiting ovulation. The total number of daily hormone units is equal to the total number of days in the desired cycle, and the number of daily units of the first hormone constituent is less than the number of daily units of the second hormone constituent. The first hormone constituent comprises 5 to 14 daily units, and the second hormone constituent comprises 23 to 14 daily units.
    Type: Grant
    Filed: October 6, 1993
    Date of Patent: April 23, 1996
    Assignees: Marika Ehrlich, Herbert Kuhl
    Inventors: Marika Ehrlich, Herbert Kuhl
  • Patent number: 5501855
    Abstract: An alternate approach to vasectomy for long term male contraception following a single intra-vas.application of a traditional plant (Azadirachta indica) product having immunomodulatory properties is described. The intra-vas administration of neem oil to male rats resulted in a block of spermatogenesis without affecting the testosterone production; the seminiferous tubules, although reduced in diameter, appeared normal and contained mostly early spermatogenic cells. No antisperm antibody could be detected in the serum. Unilateral administration of neem oil in the vas resulted in a significant reduction of testicular size and spermatogenic block only on the side of application; the draining lymph node cells of the treated side also showed enhanced proliferative response to in vitro mitogen challenge. These results indicate that intra-vas application of neem oil is effective in blocking fertility in male mammals after a single injection.
    Type: Grant
    Filed: September 2, 1993
    Date of Patent: March 26, 1996
    Inventors: Gursaran P. Talwar, Shakti N. Upadhyay, Suman Dhawan
  • Patent number: 5496829
    Abstract: 2-nitroxyethyl (+)apovincaminate is used as an agent for relieving disturbance of consciousness and as a narcotic antagonist.
    Type: Grant
    Filed: May 24, 1994
    Date of Patent: March 5, 1996
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Shigeru Okuyama, Susumu Otomo, Yutaka Kawashima, Katsuo Hatayama
  • Patent number: 5492930
    Abstract: A method for treating CNS disorders and/or improving cognitive ability in a mammal utilizing 2-phenyl-1,3-propanediol monocarbamate is disclosed. Also disclosed are formulations and methods for manufacturing this compound.
    Type: Grant
    Filed: April 25, 1994
    Date of Patent: February 20, 1996
    Assignee: Schering Corporation
    Inventor: Vicki L. Coffin
  • Patent number: 5482935
    Abstract: A method for the treatment of atherosclerosis by administering to a patient in need of anti-atherosclerotic treatment, an effective amount of 17 alpha-dihydroequilin, a C.sub.2 -C.sub.6 alkanoyloxy ester thereof or a pharmaceutically acceptable salt of it's sulfate or phosphate ester, in the absence of naturally occurring estrogenic sreroids. A pharmaceutical composition containing 17 alpha-dihydroequilin, a C.sub.2 -C.sub.6 alkanoyloxy ester thereof or a pharmaceutically acceptable salt of it's sulfate or phosphate ester, in the absence of naturally occurring estrogenic sreroids, and a pharmaceutically acceptable carrier therefor.
    Type: Grant
    Filed: December 1, 1993
    Date of Patent: January 9, 1996
    Assignee: American Home Product Corporation
    Inventors: Steven J. Adelman, Kurt E. Steiner
  • Patent number: 5480881
    Abstract: The present invention is directed to the treatment of a disease caused by an amount of pathogenic LA-paf in lipoproteins and cells comprising administering to a subject requiring the treatment an effective amount of a paf-acether antagonist.
    Type: Grant
    Filed: August 11, 1993
    Date of Patent: January 2, 1996
    Inventor: Ruth Korth
  • Patent number: 5478857
    Abstract: This invention provides methods for the treatment or prevention of Alzheimer's disease in a mammal which comprises administering to a mammal in need thereof an effective amount of an inhibitor of phospholipase A.sub.2. This invention also provides a series of compounds which are useful as inhibitors of phospholipases A.sub.2, especially cytosolic phospholipase A.sub.2.
    Type: Grant
    Filed: December 23, 1993
    Date of Patent: December 26, 1995
    Assignee: Eli Lilly and Company
    Inventors: James A. Clemens, Michael J. Sofia, Diane T. Stephenson
  • Patent number: 5478844
    Abstract: A novel aminocoumaran derivatives of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are a hydrogen atom, an acyl group, an alkoxycarbonyl group, an aliphatic group or aromatic group; R.sup.3, R.sup.4 and R.sup.5 are an optionally acylated hydroxyl optionally substituted amino group, alkoxy group or aliphatic group, or two of R.sup.3, R.sup.4 and R.sup.5 may be linked together to form a carbocyclic group; R.sup.6 and R.sup.7 are an aliphatic group and at least: one of them has a methylene group at the .alpha.-position; R.sup.8 and R.sup.9 are a hydrogen atom or an aliphatic group or aromatic group, or a salt thereof is useful for medicines for treating various diseases such as arterial sclerosis, hepatopathy, cerebrovascular diseases and the like.
    Type: Grant
    Filed: September 14, 1994
    Date of Patent: December 26, 1995
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Tetsuya Aono, Shigenori Ohkawa, Takayuki Doi
  • Patent number: 5468736
    Abstract: A method of hormone replacement therapy involves the administration of estrogen together with an amount of antiprogestin which inhibits estrogen-induced endometrial proliferation in a woman.
    Type: Grant
    Filed: February 25, 1993
    Date of Patent: November 21, 1995
    Assignee: The Medical College of Hampton Road
    Inventor: Gary D. Hodgen
  • Patent number: 5468741
    Abstract: This invention provides for novel unit doses of mifepristone to treat leiomyomata. Compared to unit dosages taught by the prior art, the claimed dosages are low and surprisingly effective. Furthermore, because higher dosages had undesired side effects, the prior art suggested that mifepristone was not suitable for long term clinical uses which are needed to treat leiomyomata. The advantages of this invention include a reduction of surgical morbidity, circumvent the need of a hysterectomy, and cost-effectiveness.
    Type: Grant
    Filed: May 28, 1993
    Date of Patent: November 21, 1995
    Assignee: The Regents of the University of California
    Inventor: Samuel S. C. Yen
  • Patent number: 5468763
    Abstract: A class of Glycine B partial agonists is described for use in memory and learning enhancement or for treatment of a cognitive disorder. Preferred Glycine B partial agonists include the compound D-cycloserine and its prodrug compounds.
    Type: Grant
    Filed: November 12, 1992
    Date of Patent: November 21, 1995
    Assignee: G. D. Searle & Co.
    Inventors: Alex A. Cordi, Gail E. Handelmann, Joseph B. Monahan
  • Patent number: 5468777
    Abstract: The present invention relates to methods and agents for preventing and reversing the staining of teeth caused by the nonenzymatic browning of proteins in the oral cavity. Suitable agents for the inhibition of nonenzymatic browning may be formulated as rinses and toothpastes, and include cysteine and cysteine derivatives. These preparations may further include known anti-plaque agents, such as chlorhexidine.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: November 21, 1995
    Assignees: The Rockefeller University, Alteon Inc.
    Inventors: Dennis S. France, Anthony Cerami, Peter C. Ulrich, Laura A. Norton, David L. Neer
  • Patent number: 5464854
    Abstract: The method of treatment moderating, blocking and/or eliminating premenstrual syndrome embodies the intermittent administering of an AT1 antagonist to a female having menstrual cycles characterized predominately by during substantially the luteal phase inclusive of at least one and frequently by two or more affective and/or autonomic and/or somatic symptoms of substantially incapacitating severity(ies) proximately substantially prior to menses of a menstrual cycle. Losartan is an example of an AT1 inhibitor and is administered either orally or parenterally continuously to a female during her menstrual cycle's luteal phase.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: November 7, 1995
    Inventor: Anathony S. dePadova
  • Patent number: 5461039
    Abstract: A method is provided for treating hypertension in normotensive patients having insulin resistance by administering a cholesterol lowering drug, such as pravastatin, alone or in combination with an ACE inhibitor, especially one containing a mercapto moiety, such as captopril or zofenopril.
    Type: Grant
    Filed: November 1, 1993
    Date of Patent: October 24, 1995
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Werner Tschollar, Cary S. Yonce, James L. Bergey, James C. Kawano
  • Patent number: 5461073
    Abstract: A septicemia suppressing substitution fluid preparation for controlling bacterial translocation of intestinal bacteria into blood containing at least one compound selected from the group consisting of (R)-3-hydroxybutyric acid and salts thereof is provided. In condition of septicemia, bacterial translocation of intestinal bacteria into blood is suppressed.
    Type: Grant
    Filed: August 22, 1994
    Date of Patent: October 24, 1995
    Assignee: Kanegafuchi Kagaku Kogyo Kabushiki Kaisha
    Inventor: Masami Katayama
  • Patent number: 5461041
    Abstract: Disclosed is an oral contraceptive regimen containing daily dosage units each containing from 70 to 80 micrograms of desogestrel, 3-ketodesogestrel or mixtures thereof. It has been found that by making a selection of desogestrel or 3-ketodesogestrel at the described dosages in an oral contraceptive regimen administered over the entire menstrual cycle (e.g. 28 days), effective ovulation inhibition is achieved and intermenstrual bleeding is avoided, while acceptable cycle control is retained. Moreover, the regimen also prevents the formation of persistent ovarian cysts.
    Type: Grant
    Filed: January 19, 1994
    Date of Patent: October 24, 1995
    Assignee: Akzo Nobel N.V.
    Inventors: Engelbert W. Bergink, Herman J. T. C. Bennink
  • Patent number: 5455275
    Abstract: The present invention provides novel methods of inhibiting uterine fibroid disease and endometriosis in women comprising administering to a woman in need of treatment an effective amount of a compound of formula I ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different provided that, when R.sup.1 and R.sup.2 are the same, each is a methyl or ethyl group, and, when R.sup.1 and R.sup.2 are different, one of them is a methyl or ethyl group and the other is a benzyl group, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 11, 1994
    Date of Patent: October 3, 1995
    Assignee: Eli Lilly and Company
    Inventor: Steven A. Fontana
  • Patent number: 5455247
    Abstract: Invented is a method of treatment of hyperlipidemia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective therefor amount of a substituted azaspirane.
    Type: Grant
    Filed: April 22, 1994
    Date of Patent: October 3, 1995
    Assignee: SmithKline Beecham Corporation
    Inventors: Peter J. Bugelski, William D. Kerns